Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology

CA Cancer J Clin. May-Jun 2010;60(3):194-201. doi: 10.3322/caac.20061. Epub 2010 Feb 2.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Androgen Antagonists / adverse effects*
  • Androgen Antagonists / therapeutic use
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Cardiovascular Diseases / chemically induced*
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / mortality
  • Humans
  • Male
  • Morbidity
  • Prostatic Neoplasms / drug therapy*
  • Risk Assessment
  • Risk Factors
  • United States / epidemiology

Substances

  • Androgen Antagonists
  • Antineoplastic Agents